Physician profile
Daniel Kessel
NPI 1063449700
$605.22
in general payments reported to CMS, 2019-2025
10 companies · $213 in 2025
The $213 reported for 2025 was more than what a typical provider received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $100 · 2020: $39.47 · 2021: $72.72 · 2022: $18.25 · 2023: $72.00 · 2024: $89.32 · 2025: $213.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $303 · Education: $72.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $302.78 |
| Education | $72.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $218.16 | 2019-2025 | |
| Allergan, INC. | $102.36 | 2020-2022 | |
| Strata Skin Sciences, INC. | $95.06 | 2025 | Xtrac |
| Janssen Biotech, INC. | $72.00 | 2023 | Tremfya |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $57.57 | 2019-2020 | |
| Pfizer INC. | $27.52 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $14.84 | 2019 | |
| Mayne Pharma Commercial LLC | $13.27 | 2019 | |
| Organon LLC | $4.44 | 2025 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$1,151,240.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Kessel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.